Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Sandoz Generics Company Intelligence Report
Management Report
Published: March 2009
Pages: 16
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 195.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation.
Sandoz is a subsidiary of Novartis, now headquartered in Germany. The subsidiary was formerly a collection of companies under the Novartis Generics umbrella name, but a major rebranding and reorganisation process began in 2002.
Sandoz is currently the second largest generic manufacturer in the world, behind Teva Pharmaceutical Industries. The company completed its acquisition of Hexal and Eon Labs in June 2005, in one of the generic industry’s largest mergers to date.
Major production sites are in Austria, the USA, Germany and Slovenia. Around two thirds of the company’s workforce is based in Europe. The US subsidiary was formerly known as Geneva Pharmaceuticals, owned by Novartis since 1979. Novartis purchased the major Slovenian producer, Lek, in 2003. Lek has a major presence in the CEE region.
Sandoz is a frontrunner in the development of biosimilar products. Its human growth hormone product, Omnitrope, was approved in 2006, and the company has followed this with European approval of EPO in 2007 and G-CSF in 2008. Lek began constructing a new biotech plant in Slovenia in September 2006, and a new injectables facility has recently been announced in Canada.
Sandoz had sales in 2008 worth US$7.6 billion, 5.4% less than in 2007. The firm reported good growth in markets such as Russia, Brazil and Central and Eastern Europe, but declining sales in the US and some Western European markets. Sales in the US fell by nearly 10%.
Sandoz is currently the second largest generic manufacturer in the world, behind Teva Pharmaceutical Industries. The company completed its acquisition of Hexal and Eon Labs in June 2005, in one of the generic industry’s largest mergers to date.
Major production sites are in Austria, the USA, Germany and Slovenia. Around two thirds of the company’s workforce is based in Europe. The US subsidiary was formerly known as Geneva Pharmaceuticals, owned by Novartis since 1979. Novartis purchased the major Slovenian producer, Lek, in 2003. Lek has a major presence in the CEE region.
Sandoz is a frontrunner in the development of biosimilar products. Its human growth hormone product, Omnitrope, was approved in 2006, and the company has followed this with European approval of EPO in 2007 and G-CSF in 2008. Lek began constructing a new biotech plant in Slovenia in September 2006, and a new injectables facility has recently been announced in Canada.
Sandoz had sales in 2008 worth US$7.6 billion, 5.4% less than in 2007. The firm reported good growth in markets such as Russia, Brazil and Central and Eastern Europe, but declining sales in the US and some Western European markets. Sales in the US fell by nearly 10%.